Firms, funds, people, portfolio companies and transactions from sworn filings and cited announcements, kept as a graph with a date and a source on every edge. Reported gross assets are never fund size, regulatory AUM is never dry powder, and a deal value prints only when someone disclosed it.

The names on this page are hidden. Create a free account and they fill in. No card, and every figure, date and source on this page is public either way.

Transactions / i•••• l•••

I•••• L••• Investment from BroadOak BioTools Venture Fund

Type not statedclosedannounced Apr 12, 2023closed Apr 12, 2023Fact
What happened
Target
i•••• l•••
Platform
not an add-on on record
Control
unknown
Share acquired
unknown
Industry
unknown
Target location
unknown
Seller kind
unknown
Rollover
unknown
Values, only where disclosed
Enterprise value
Not disclosed
Purchase price
Not disclosed
Equity value
Not disclosed
Target revenue
Not disclosed
Target EBITDA
Not disclosed
Multiple
Not disclosed
Parties and roles
3 named
Buy side
  • B••••••• A•••• M••••••••• L••Sponsorconfirmed
    “BroadOak Capital Partners invested in I•••• L••• out of its BioTools Venture Fund to support the development of Hydropore, which enables modified immune cell research and development with improved yield and function using a simple workflow, commercial GMP-grade buffers and a small footprint. | publi”
Side not stated
  • R••• P•••••Managementconfirmed
    “Cumulatively, we believe both teams will accelerate and improve the further development of the Hydropore Cell Therapy platform," stated R••• P•••••, CEO of I•••• L•••.”
  • i•••• l•••Targetconfirmed
    “BroadOak Capital Partners invested in I•••• L••• out of its BioTools Venture Fund to support the development of Hydropore, which enables modified immune cell research and development with improved yield and function using a simple workflow, commercial GMP-grade buffers and a small footprint.”
Evidence
“BroadOak Capital Partners invested in I•••• L••• out of its BioTools Venture Fund to support the development of Hydropore, which enables modified immune cell research and development with improved yield and function using a simple workflow, commercial GMP-grade buffers and a small footprint.”
Press release wires (PR Newswire, GlobeNewswire, Business Wire public pages and RSS)confidence 80%recorded Sep 18, 2026
I•••• L••• Investment from BroadOak BioTools Venture Fund | Private Equity Intelligence | DFX